Prediction of outcomes after second-line treatment for acute graft-versus-host disease
Last Updated: Wednesday, June 8, 2022
An examination of overall survival (OS) and failure-free-survival (FFS) of 216 patients who received allogenic hematopoietic cell transplantation and required second-line treatment for acute GvHD had estimated points of OS and FFS at six months of 64% and 46%, respectively.
Advertisement
News & Literature Highlights